Citations

Clear

63 citation(s) found for "Smith, Steven".

Follicular Dendritic Cell Sarcoma With NF2 Mutation
Karrs, Jeremiah , Gohlke, Amanda Lynn, Oliveira, André M. , Richard, Hope , Pavlick, Dean C. , Smith, Steven C. , Poklepovic, Andrew

Mayo Clinic

AJSP: Reviews and Reports | October 16, 2018 | Volume: 23 | Issue: 6 | Pages: 251-254

10.1097/pcr.0000000000000277 Get It

Abstract Follicular dendritic cell sarcoma (FDCS) is recognized as a diagnostically challenging neoplasm requiring rigorous exclusion of more common entities and high index of suspicion for diagnosis. Here, we report an aggressive case of FDCS arising in the mediastinum, which due to sampling limitations and the inherent difficulty of diagnosis required extensive workup with multiple samples prior to definitive classification. The patient was a 35-year-old woman who presented with progressive dyspnea and mediastinal mass on imaging studies. The initial sampling of the lesion had histologic features raising consideration of FDCS, but was too limited to allow definitive diagnosis, while progressing rapidly enough to require administration of chemotherapy even prior to classification. Repeat samples obtained via fine-needle aspiration and bronchoscopy enabled the diagnosis of FDCS, and high-throughput sequencing revealed apparently pathogenic NF2 mutations previously not reported in this disease. Unfortunately, the patient died of widely metastatic disease, which we comprehensively documented at autopsy. Together, these observations provide previously unreported insights into the end stage of this disease and experience relevant to its prospective recognition and workup.
Linear yellow papules following a cat scratch
Lehman, Julia S. , Nault, Ashley M., Smith, Steven A., McEvoy, Marian T., Lehman, Julia S

Mayo Clinic

International Journal of Dermatology | February 16, 2018 | Volume: 57 | Issue: 7 | Pages: 862-863

10.1111/ijd.13944 | PMID 29450887 Get It

Using claims data linked with electronic health records to monitor and improve adherence to medication
Lobo, Jennifer M. , Wilson, James R. , Shah, N. D., Smith, Steven A., Denton, Brian T.

Mayo Clinic

IISE Transactions on Healthcare Systems Engineering | June 29, 2017 | Volume: 7 | Issue: 4 | Pages: 194-214

10.1080/24725579.2017.1346728 Get It

Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF
Jasim, Sina , Smith, Steven A.

Mayo Clinic

Annals of Internal Medicine | April 18, 2017 | Volume: 166 | Issue: 8 | Pages: JC46

10.7326/acpjc-2017-166-8-046 | PMID 28418548 Get It

Development and Validation of HealthImpact: An Incident Diabetes Prediction Model Based on Administrative Data
Nori, Vijay S. , Smith, Steven A., Hane, Christopher A. , McCoy, Rozalina G.

Mayo Clinic

Health Services Research | February 21, 2016 | Volume: 51 | Issue: 5 | Pages: 1896-1918

10.1111/1475-6773.12461 | PMID 26898782 Get It

Objective To develop and validate a model of incident type 2 diabetes based solely on administrative data. Data Sources/Study Setting Optum Labs Data Warehouse (OLDW), a national commercial administrative dataset. Study Design HealthImpact model was developed and internally validated using nested case–control study design; n = 473,049 in training cohort and n = 303,025 in internal validation cohort. HealthImpact was externally validated in 2,000,000 adults followed prospectively for 3 years. Only adults ≥18 years were included. Data Collection/Extraction Methods Patients with incident diabetes were identified using HEDIS rules. Control subjects were sampled from patients without diabetes. Medical and pharmacy claims data collected over 3 years prior to index date were used to build the model variables. Principal Findings HealthImpact, scored 0–100, has 48 variables with c‐statistic 0.80815. We identified HealthImpact threshold of 90 as identifying patients at high risk of incident diabetes. HealthImpact had excellent discrimination in external validation cohort (c‐statistic 0.8171). The sensitivity, specificity, positive predictive value, and negative predictive value of HealthImpact >90 for new diagnosis of diabetes within 3 years were 32.35, 94.92, 22.25, and 96.90 percent, respectively. Conclusions HealthImpact is an efficient and effective method of risk stratification for incident diabetes that is not predicated on patient‐provided information or laboratory tests.
Mealtime Insulin Dosing by Carbohydrate Counting in Hospitalized Cardiology Patients: A Retrospective Cohort Study
Thurber, Kristina M., Dierkhising, Ross , Reiland, Sarah , Pearson, Kristina K., Smith, Steven A., O’Meara, John G. , Dierkhising, Ross A, Reiland, Sarah A

Mayo Clinic

Diabetes Technology & Therapeutics | July 31, 2015 | Volume: 18 | Issue: 1 | Pages: 15-21

10.1089/dia.2015.0103 | PMID 26230278 Get It

Background: Carbohydrate counting may improve glycemic control in hospitalized cardiology patients by providing individualized insulin doses tailored to meal consumption. The purpose of this study was to compare glycemic outcomes with mealtime insulin dosed by carbohydrate counting versus fixed dosing in the inpatient setting. Materials and Methods: This single-center retrospective cohort study included 225 adult medical cardiology patients who received mealtime, basal, and correction-scale insulin concurrently for at least 72 h and up to 7 days in the interval March 1, 2010–November 7, 2013. Mealtime insulin was dosed by carbohydrate counting or with fixed doses determined prior to meal intake. An inpatient diabetes consult service was responsible for insulin management. Exclusion criteria included receipt of an insulin infusion. The primary end point compared mean daily postprandial glucose values, whereas secondary end points included comparison of preprandial glucose values and mean daily rates of hypoglycemia. Results: Mean postprandial glucose level on Day 7 was 204 and 183 mg/dL in the carbohydrate counting and fixed mealtime dose groups, respectively (unadjusted P =0.04, adjusted P =0.12). There were no statistical differences between groups on Days 2–6. Greater rates of preprandial hypoglycemia were observed in the carbohydrate counting cohort on Day 5 (8.6% vs. 1.5%, P =0.02), Day 6 (1.7% vs. 0%, P =0.01), and Day 7 (7.1% vs. 0%, P =0.008). No differences in postprandial hypoglycemia were seen. Conclusions: Mealtime insulin dosing by carbohydrate counting was associated with similar glycemic outcomes as fixed mealtime insulin dosing, except for a greater incidence of preprandial hypoglycemia. Additional comparative studies that include hospital outcomes are needed.
Review: Intensive blood pressure control reduces retinopathy in diabetes
Smith, Steven A., Tamhane, Shrikant

Mayo Clinic

Annals of Internal Medicine | June 15, 2015 | Volume: 162 | Issue: 12 | Pages: JC7

10.7326/acpjc-2015-162-12-007 | PMID 26075784 Get It

MEN1 Mutations in Hürthle Cell (Oncocytic) Thyroid Carcinoma
Kasaian, Katayoon, Chindris, Ana-Maria, Wiseman, Sam M. , Mungall, Karen , Zeng, Thomas, Tse, Kane, Schein, Jacqueline E., Rivera, Michael , Necela, Brian M. , Kachergus, Jennifer M., Casler, John D., Mungall, Andrew J. , Moore, Richard A. , Marra, Marco A. , Copland, John A. , Thompson, E. Aubrey , Smallridge, Robert C., Jones, Steven J.M. , Kasaian, Katayoon, Chindris, Ana-Maria , Mungall, Andrew J

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 27, 2015 | Volume: 100 | Issue: 4 | Pages: E611-E615

10.1210/jc.2014-3622 | PMID 25625803 Get It

Context and Objective:Oncocytic thyroid carcinoma, also known as Hürthle cell thyroid carcinoma, accounts for only a small percentage of all thyroid cancers. However, this malignancy often presents at an advanced stage and poses unique challenges to patients and clinicians. Surgical resection of the tumor accompanied in some cases by radioactive iodine treatment, radiation, and chemotherapy are the established modes of therapy. Knowledge of the perturbed oncogenic pathways can provide better understanding of the mechanism of disease and thus opportunities for more effective clinical management.Design and Patients:Initially, two oncocytic thyroid carcinomas and their matched normal tissues were profiled using whole genome sequencing. Subsequently, 72 oncocytic thyroid carcinomas, one cell line, and five Hürthle cell adenomas were examined by targeted sequencing for the presence of mutations in the multiple endocrine neoplasia I (MEN1) gene.Results:Here we report the identification of MEN1 loss-of-function mutations in 4% of patients diagnosed with oncocytic thyroid carcinoma. Whole genome sequence data also revealed large regions of copy number variation encompassing nearly the entire genomes of these tumors.Conclusion:Menin, a ubiquitously expressed nuclear protein, is a well-characterized tumor suppressor whose loss is the cause of MEN1 syndrome. Menin is involved in several major cellular pathways such as regulation of transcription, control of cell cycle, apoptosis, and DNA damage repair pathways. Mutations of this gene in a subset of Hürthle cell tumors point to a potential role for this protein and its associated pathways in thyroid tumorigenesis.
Response to Comments on Zhang et al. Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Diabetes Care 2014;37:1338–1345
Zhang, Yuanhui , Mason, Jennifer, Smith, Steven A., Shah, Nilay D. , McCoy, Rozalina G. , Denton, Brian T.

Mayo Clinic

Diabetes Care | August 21, 2014 | Volume: 37 | Issue: 9 | Pages: e206-e207

10.2337/dc14-1339 | PMID 25147267 Get It

Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment
Smith, Steven C. , McCoy, Rozalina G.

Mayo Clinic

Annals of Internal Medicine | August 18, 2014 | Volume: 161 | Issue: 4 | Pages: JC2

10.7326/0003-4819-161-4-201408190-02002 | PMID 25133381 Get It